Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Nextblockbuster

Rank: President [?]

Points: 2717 [?]

Votes: 15 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference

in response to

Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference

BearDownAZ

posted on Jun 21, 2022 09:16AM

Question to the board,

With all this very positive science news coming from Zenith over the past several years , What are the BP's waiting for to lock in this epigenetic technology in a full 100% partnership or buyout??? What are the BP's waiting for one of their peers to take a leap first?? or more data for confirmation....

5 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply